# Polarity effects, resistance, and probiotic enhancement of intoxication of Salmonella enterica fraB mutants in murine models

## TL;DR

Researchers found that a Salmonella mutant (fraB) is toxic when exposed to fructose-asparagine (F-Asn), and combining it with a probiotic strain and F-Asn could be a new treatment for Salmonella infections.

## Contribution

The study introduces a novel therapeutic strategy using a FraB inhibitor, F-Asn, and a probiotic to treat Salmonella infections.

## Key findings

- A non-polar fraB mutant (FraB E214A) is toxic to Salmonella when F-Asn is present.
- High-fat diets reduce colonization variation in Salmonella-infected mice due to lack of F-Asn.
- A probiotic strain combined with F-Asn reduces Salmonella CFU and inflammation markers significantly.

## Abstract

FraB is a deglycase in a metabolic pathway that allows Salmonella to utilize fructose-asparagine (F-Asn). Some fraB mutants are sensitive to F-Asn due to the accumulation of 6-phosphofructose-aspartate (6-P-F-Asp), a toxic intermediate in this pathway. We determined that different alleles of fraB cause different amounts of 6-P-F-Asp-mediated toxicity due to effects on the expression of the downstream gene, fraD, a kinase. Mutations in fraD or fraA (a transporter) cause resistance to F-Asn intoxication, and these mutations occur during infection. To better mimic the effect of a hypothetical FraB inhibitor in mouse models, we characterized a non-polar mutant encoding a catalytically inactive FraB (FraB E214A). We also compared a typical mouse chow and a high-fat chow and found that the latter decreases the variation in colonization typically observed during infection of CBA/J mice with Salmonella. Because the high-fat chow lacks F-Asn, the fraB E214A mutant was not attenuated in mice fed this diet unless F-Asn was supplemented. F-Asn supplementation resulted in a 100-fold reduction of colony forming units (CFU) recovered from feces compared to wild-type. Co-infection of Salmonella with a Salmonella “probiotic” strain that is neither virulent nor capable of consuming F-Asn (a SPI1 SPI2 fraR-BDAE ansB mutant) led to a dramatic 10,000-fold reduction in CFU and a 1000-fold reduction in lipocalin-2, a proxy marker of inflammation. This probiotic strain presumably competes for nutrients other than F-Asn, driving the fraB mutant to consume a higher proportion of F-Asn and greater 6-P-F-Asp intoxication. Thus, a putative inhibitor of FraB, when administered with F-Asn and a probiotic, may provide a new therapeutic strategy for treating Salmonella gastroenteritis.